文献速递眼底病与葡萄膜炎

继发于年龄相关性黄斑变性的地图样萎缩患者视网膜下细胞治疗的经验

Experience With a Subretinal Cell-based Therapy in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2017-04-21

这项1/2a期多中心开放标签剂量递增对侧眼对照研究,评估单次视网膜下人脐带组织来源细胞(palucorcel)治疗50岁以上双侧地图样萎缩患者的安全性与临床反应。35例受试者中33眼接受细胞给药,17.1%(6/35)发生视网膜脱离,37.1%(13/35)发生视网膜穿孔;未观察到免疫排斥或肿瘤形成。1年时给药眼最佳矫正视力≥10字母和≥15字母增益分别为34.5%(10/29)和24.1%(7/29),对侧眼均为3.3%(1/30)。作者认为需更大样本随机对照研究确认结果,未来研究需改良手术方式。

要点

  • 视网膜下给药手术相关视网膜穿孔13例、视网膜脱离6例,发生率较高。
  • 细胞局限于视网膜下间隙时palucorcel耐受良好,可能与视力改善相关。
  • 1年时给药眼视力增益高于对侧眼,但研究为开放标签对侧眼对照。

核心结论

  • 本研究的视网膜下给药手术与较高的视网膜穿孔(n=13)和视网膜脱离(n=6)发生率相关。
  • 当细胞局限于视网膜下间隙时,palucorcel耐受良好,可能与视力改善相关。
  • 作者指出需更大样本随机对照研究确认这些结果,未来研究需改良手术方式。

研究设计与样本

  • 1/2a期、多中心、开放标签、剂量递增、对侧眼对照研究。
  • 纳入年龄≥50岁、继发于年龄相关性黄斑变性的双侧地图样萎缩成人患者,共35例合格受试者至少接受部分手术操作。
  • 1期部分每眼接受单次视网膜下palucorcel剂量范围为6.0×10^4至5.6×10^5个活细胞;2a期部分每眼接受6.0×10^4或3.0×10^5个细胞两种剂量之一。
  • 干预眼为基线视力较差眼,palucorcel实际给药33眼。

主要发现

  • 总体17.1%(6/35)受试者发生视网膜脱离,37.1%(13/35)发生视网膜穿孔。
  • 未观察到免疫排斥或肿瘤形成事件。
  • 1年时,接受palucorcel眼最佳矫正视力≥10字母增益为34.5%(10/29),≥15字母增益为24.1%(7/29)。
  • 1年时,对侧眼最佳矫正视力≥10字母和≥15字母增益均为3.3%(1/30)。

临床怎么用

  • 原文结论指出本研究视网膜下给药手术与较高的视网膜穿孔和视网膜脱离发生率相关。
  • 原文结论指出当细胞局限于视网膜下间隙时palucorcel耐受良好,可能与视力改善相关。
  • 作者指出需更大样本随机对照研究确认结果,未来研究需改良手术方式。

局限性

  • 原文指出需更大样本随机对照研究确认这些结果。
  • 原文指出未来研究需改良手术方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and tolerability of and clinical response to a single, subretinal dose of human umbilical tissue-derived cells (palucorcel [CNTO-2476]) in the eyes of adults aged ≥50 years with bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD). DESIGN: Phase 1/2a, multicenter, open-label, dose-escalation, fellow-eye-controlled study. METHODS: In the phase 1 portion, eyes were assigned to receive a single, subretinal dose of palucorcel (ranging from 6.0 × 104 to 5.6 × 105 viable cells). In the phase 2a portion, eyes were assigned to one of 2 palucorcel doses (6.0 × 104 or 3.0 × 105 cells) determined during the phase 1 portion. The intervention eye was the eye with worse baseline visual acuity. RESULTS: A total of 35 eligible subjects underwent at least a partial surgical procedure. Palucorcel was administered in 33 eyes. Overall, 17.1% (6/35) of subjects experienced retinal detachments and 37.1% (13/35) experienced retinal perforations. No episodes of immune rejection or tumor formation were observed. At 1 year, ≥10- and ≥15-letter gains in best-corrected visual acuity were observed in 34.5% (10/29) and 24.1% (7/29) of eyes receiving palucorcel, respectively, and in 3.3% (1/30; for both) of fellow eyes. CONCLUSIONS: The subretinal delivery procedure in this study was associated with a high rate of retinal perforations (n = 13) and retinal detachments (n = 6). When cells were sequestered in the subretinal space, palucorcel was well tolerated and may be associated with improvements in visual acuity. Larger randomized controlled studies are required to confirm these results. Future studies would require a modified surgical approach.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ho AC, Chang TS, Samuel M, et al. Experience With a Subretinal Cell-based Therapy in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration. Am J Ophthalmol. 2017. PMID: 28435054. doi:10.1016/j.ajo.2017.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。